Sintilimab plus IBI305 for hepatocellular carcinoma

Research output: Contribution to journal › Letter › peer-review

Access to Document

@article{813f5c9e4d3a40fbb6a6d5fe1d0d2416,

title = "Sintilimab plus IBI305 for hepatocellular carcinoma",

author = "David Bomze and Tomer Meirson and Daniel Azoulay",

year = "2021",

month = sep,

doi = "10.1016/s1470-2045(21)00388-0",

language = "אנגלית",

volume = "22",

pages = "e386",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "9",

}

TY - JOUR

T1 - Sintilimab plus IBI305 for hepatocellular carcinoma

AU - Bomze, David

AU - Meirson, Tomer

AU - Azoulay, Daniel

PY - 2021/9

Y1 - 2021/9

UR - https://www.scopus.com/pages/publications/85114054860

U2 - 10.1016/s1470-2045(21)00388-0

DO - 10.1016/s1470-2045(21)00388-0

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 34478670

AN - SCOPUS:85114054860

SN - 1470-2045

VL - 22

SP - e386

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 9

ER -